Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SILK

Silk Road Medical (SILK) Stock Price, News & Analysis

Silk Road Medical logo

About Silk Road Medical Stock (NASDAQ:SILK)

Advanced Chart

Key Stats

Today's Range
$27.49
$27.49
50-Day Range
$27.01
$27.50
52-Week Range
$6.08
$27.51
Volume
N/A
Average Volume
1.20 million shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00
Consensus Rating
Reduce

Company Overview

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Silk Road Medical Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
9th Percentile Overall Score

SILK MarketRank™: 

Silk Road Medical scored higher than 9% of companies evaluated by MarketBeat, and ranked 933rd out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Silk Road Medical has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Silk Road Medical has received no research coverage in the past 90 days.

  • Read more about Silk Road Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Silk Road Medical are expected to grow in the coming year, from ($1.45) to ($1.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Silk Road Medical is -20.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Silk Road Medical is -20.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Silk Road Medical has a P/B Ratio of 7.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SILK.
  • Dividend Yield

    Silk Road Medical does not currently pay a dividend.

  • Dividend Growth

    Silk Road Medical does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for SILK.
    Receive SILK Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Silk Road Medical and its competitors with MarketBeat's FREE daily newsletter.

    SILK Stock News Headlines

    Is this Elon’s true agenda?
    All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell them
    Trump pardons founder of Silk Road website
    See More Headlines

    SILK Stock Analysis - Frequently Asked Questions

    Silk Road Medical, Inc (NASDAQ:SILK) released its earnings results on Wednesday, August, 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.04. The firm's revenue was up 13.0% on a year-over-year basis.

    Silk Road Medical (SILK) raised $75 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Silk Road Medical investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

    Company Calendar

    Last Earnings
    8/07/2024
    Today
    2/01/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Surgical & medical instruments
    Sub-Industry
    Medical Equipment
    Current Symbol
    NASDAQ:SILK
    Employees
    410
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $24.00
    High Stock Price Target
    $27.50
    Low Stock Price Target
    $20.00
    Potential Upside/Downside
    -12.7%
    Consensus Rating
    Reduce
    Rating Score (0-4)
    1.80
    Research Coverage
    5 Analysts

    Profitability

    Net Income
    $-55,740,000.00
    Pretax Margin
    -29.53%

    Debt

    Sales & Book Value

    Annual Sales
    $177.13 million
    Book Value
    $3.88 per share

    Miscellaneous

    Free Float
    37,906,000
    Market Cap
    $1.12 billion
    Optionable
    Optionable
    Beta
    1.53
    20 Stocks to Sell Now Cover

    MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

    Get This Free Report

    This page (NASDAQ:SILK) was last updated on 2/1/2025 by MarketBeat.com Staff
    From Our Partners